Share Price and Basic Stock Data
Last Updated: November 28, 2025, 8:36 am
| PEG Ratio | 0.77 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Kilitch Drugs (India) Ltd operates in the pharmaceuticals sector, focusing on manufacturing and marketing a range of pharmaceutical products. The company’s revenue trajectory has shown a consistent upward trend, with reported sales of ₹140 Cr for the fiscal year ending March 2023, up from ₹114 Cr in the previous year. This growth continued into fiscal 2024, with sales rising to ₹154 Cr, and further projected to reach ₹198 Cr in fiscal 2025. The quarterly performance reflects this positive trend, with sales for September 2023 reported at ₹41.20 Cr, marking a significant recovery from ₹30.70 Cr in September 2022. The company has maintained a steady increase in sales, with the trailing twelve months (TTM) revenue reported at ₹209 Cr, indicating a robust demand for its products and an effective expansion strategy in a competitive market.
Profitability and Efficiency Metrics
Kilitch Drugs has demonstrated commendable profitability metrics, with a net profit of ₹25 Cr for the fiscal year ending March 2025, compared to ₹14 Cr in fiscal 2024. The net profit margin has improved to 12.57%, reflecting effective cost management and operational efficiencies. The operating profit margin (OPM) stood at 16% for fiscal 2024, showcasing the company’s ability to control expenses relative to its revenue. Furthermore, the interest coverage ratio (ICR) was a strong 8.46x, indicating the company’s capability to meet its interest obligations comfortably. The return on equity (ROE) was reported at 12.6%, while return on capital employed (ROCE) was 15.7%, both of which are favorable compared to many industry peers, suggesting efficient utilization of capital and strong operational performance.
Balance Sheet Strength and Financial Ratios
The financial health of Kilitch Drugs is supported by a solid balance sheet, with total assets reported at ₹313 Cr and total liabilities at ₹240 Cr for fiscal 2025. The company has maintained a conservative approach to debt, with total borrowings standing at ₹49 Cr, resulting in a total debt-to-equity ratio of 0.24x, which is low relative to industry standards. The company’s reserves have also seen a steady increase, reported at ₹186 Cr in fiscal 2025, providing a buffer against potential downturns. The current ratio was reported at 2.06x, indicating strong liquidity, while the quick ratio was at 1.88x, suggesting that the company can cover its short-term liabilities comfortably. The price-to-book value (P/BV) ratio stood at 2.87x, reflecting market confidence in the company’s equity value.
Shareholding Pattern and Investor Confidence
Kilitch Drugs has a stable shareholding structure, with promoters holding a significant 63.77% stake as of March 2025, which reflects strong control and commitment from the founding members. The public shareholding has increased to 36.22%, indicating growing investor interest, with the total number of shareholders rising to 10,929. This upward trend in public participation can be seen as a positive indicator of investor confidence in the company’s growth prospects. Notably, foreign institutional investors (FIIs) and domestic institutional investors (DIIs) do not hold a stake, which may limit diversification but also suggests that the company has not yet attracted significant institutional backing. The steady increase in public ownership, combined with a strong promoter presence, may foster a more resilient share price moving forward, as more retail investors engage with the stock.
Outlook, Risks, and Final Insight
Looking ahead, Kilitch Drugs is well-positioned for continued growth, driven by its expanding product portfolio and increasing market share in the pharmaceutical sector. However, risks remain, including potential regulatory challenges and competition from larger players in the industry. The company’s reliance on a limited number of product lines could also pose a risk if market dynamics shift. Additionally, while the financial metrics are strong, any downturn in sales or increased operational costs could impact profitability. Therefore, maintaining operational efficiency will be crucial. In scenarios where the company successfully expands its product offerings and enters new markets, it could significantly enhance its revenue base. Conversely, failure to manage costs or adapt to competitive pressures could hinder growth and profitability. Overall, Kilitch Drugs showcases strong fundamentals but must navigate industry challenges carefully to sustain its upward trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Kilitch Drugs (India) Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 149 Cr. | 118 | 247/84.3 | 32.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,425 Cr. | 406 | 479/192 | 91.6 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.0 Cr. | 44.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 42.5 Cr. | 29.0 | 29.3/17.0 | 101 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,561.99 Cr | 1,174.44 | 52.22 | 202.44 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33.45 | 30.70 | 29.97 | 45.48 | 36.56 | 41.20 | 31.79 | 44.82 | 33.45 | 47.47 | 56.17 | 61.23 | 43.14 |
| Expenses | 30.03 | 26.75 | 25.99 | 39.26 | 30.38 | 32.58 | 29.51 | 37.74 | 31.79 | 41.37 | 47.44 | 46.64 | 39.88 |
| Operating Profit | 3.42 | 3.95 | 3.98 | 6.22 | 6.18 | 8.62 | 2.28 | 7.08 | 1.66 | 6.10 | 8.73 | 14.59 | 3.26 |
| OPM % | 10.22% | 12.87% | 13.28% | 13.68% | 16.90% | 20.92% | 7.17% | 15.80% | 4.96% | 12.85% | 15.54% | 23.83% | 7.56% |
| Other Income | 0.97 | 0.24 | 0.69 | 1.02 | 0.56 | 0.49 | 2.96 | 0.47 | 2.57 | 5.16 | 1.73 | 1.70 | 2.56 |
| Interest | 0.67 | 1.75 | 1.29 | 1.21 | 1.50 | 1.51 | 1.60 | 1.32 | 1.73 | 0.31 | 1.40 | 1.60 | 1.53 |
| Depreciation | 0.82 | 0.89 | 0.93 | 0.91 | 0.71 | 0.82 | 0.81 | 0.93 | 0.85 | 0.61 | 0.81 | 0.85 | 0.84 |
| Profit before tax | 2.90 | 1.55 | 2.45 | 5.12 | 4.53 | 6.78 | 2.83 | 5.30 | 1.65 | 10.34 | 8.25 | 13.84 | 3.45 |
| Tax % | 40.00% | -25.16% | 30.61% | 43.16% | 32.67% | 24.93% | 38.16% | 30.57% | 93.33% | 16.73% | 32.00% | 26.23% | 34.49% |
| Net Profit | 1.74 | 1.94 | 1.71 | 2.90 | 3.06 | 5.09 | 1.74 | 3.68 | 0.11 | 8.61 | 5.61 | 10.22 | 2.27 |
| EPS in Rs | 1.24 | 1.44 | 1.40 | 2.11 | 1.99 | 2.71 | 1.66 | 2.05 | 0.77 | 4.93 | 3.41 | 5.94 | 1.73 |
Last Updated: August 20, 2025, 8:10 am
Below is a detailed analysis of the quarterly data for Kilitch Drugs (India) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 43.14 Cr.. The value appears to be declining and may need further review. It has decreased from 61.23 Cr. (Mar 2025) to 43.14 Cr., marking a decrease of 18.09 Cr..
- For Expenses, as of Jun 2025, the value is 39.88 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 46.64 Cr. (Mar 2025) to 39.88 Cr., marking a decrease of 6.76 Cr..
- For Operating Profit, as of Jun 2025, the value is 3.26 Cr.. The value appears to be declining and may need further review. It has decreased from 14.59 Cr. (Mar 2025) to 3.26 Cr., marking a decrease of 11.33 Cr..
- For OPM %, as of Jun 2025, the value is 7.56%. The value appears to be declining and may need further review. It has decreased from 23.83% (Mar 2025) to 7.56%, marking a decrease of 16.27%.
- For Other Income, as of Jun 2025, the value is 2.56 Cr.. The value appears strong and on an upward trend. It has increased from 1.70 Cr. (Mar 2025) to 2.56 Cr., marking an increase of 0.86 Cr..
- For Interest, as of Jun 2025, the value is 1.53 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.60 Cr. (Mar 2025) to 1.53 Cr., marking a decrease of 0.07 Cr..
- For Depreciation, as of Jun 2025, the value is 0.84 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.85 Cr. (Mar 2025) to 0.84 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 3.45 Cr.. The value appears to be declining and may need further review. It has decreased from 13.84 Cr. (Mar 2025) to 3.45 Cr., marking a decrease of 10.39 Cr..
- For Tax %, as of Jun 2025, the value is 34.49%. The value appears to be increasing, which may not be favorable. It has increased from 26.23% (Mar 2025) to 34.49%, marking an increase of 8.26%.
- For Net Profit, as of Jun 2025, the value is 2.27 Cr.. The value appears to be declining and may need further review. It has decreased from 10.22 Cr. (Mar 2025) to 2.27 Cr., marking a decrease of 7.95 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.73. The value appears to be declining and may need further review. It has decreased from 5.94 (Mar 2025) to 1.73, marking a decrease of 4.21.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:01 am
| Metric | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 108 | 19 | 21 | 27 | 51 | 82 | 53 | 68 | 114 | 140 | 154 | 198 | 209 |
| Expenses | 95 | 21 | 25 | 28 | 45 | 75 | 53 | 63 | 104 | 122 | 130 | 167 | 178 |
| Operating Profit | 13 | -2 | -4 | -1 | 6 | 7 | 0 | 5 | 10 | 18 | 24 | 32 | 32 |
| OPM % | 12% | -9% | -19% | -2% | 11% | 9% | 1% | 8% | 9% | 13% | 16% | 16% | 15% |
| Other Income | 92 | 3 | 2 | 1 | 3 | 4 | 4 | 3 | 3 | 3 | 4 | 11 | 13 |
| Interest | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 6 | 5 | 6 |
| Depreciation | 5 | 2 | 10 | 10 | 2 | 2 | 2 | 2 | 2 | 4 | 3 | 3 | 3 |
| Profit before tax | 97 | -1 | -12 | -9 | 6 | 9 | 2 | 5 | 10 | 12 | 19 | 34 | 35 |
| Tax % | 22% | -70% | -4% | -5% | 16% | 55% | 48% | 27% | 35% | 31% | 30% | 28% | |
| Net Profit | 76 | -0 | -11 | -9 | 5 | 4 | 1 | 4 | 6 | 8 | 14 | 25 | 26 |
| EPS in Rs | 52.99 | -0.20 | -7.77 | -6.17 | 3.46 | 2.29 | 0.50 | 2.18 | 4.36 | 6.18 | 8.34 | 15.26 | 15.77 |
| Dividend Payout % | 52% | 0% | 0% | 0% | 13% | 20% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 18.18% | 155.56% | -20.00% | -75.00% | 300.00% | 50.00% | 33.33% | 75.00% | 78.57% |
| Change in YoY Net Profit Growth (%) | 0.00% | 137.37% | -175.56% | -55.00% | 375.00% | -250.00% | -16.67% | 41.67% | 3.57% |
Kilitch Drugs (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 30% |
| 3 Years: | 20% |
| TTM: | 38% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 43% |
| 5 Years: | 164% |
| 3 Years: | 60% |
| TTM: | 123% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 33% |
| 3 Years: | 30% |
| 1 Year: | 9% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 8% |
| 3 Years: | 10% |
| Last Year: | 14% |
Last Updated: September 5, 2025, 9:05 am
Balance Sheet
Last Updated: June 16, 2025, 11:50 am
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 14 | 15 | 15 | 15 | 16 | 16 | 16 | 16 |
| Reserves | 101 | 107 | 95 | 88 | 98 | 106 | 103 | 112 | 124 | 136 | 160 | 186 |
| Borrowings | 9 | 0 | 0 | 1 | 1 | 9 | 13 | 15 | 20 | 22 | 32 | 49 |
| Other Liabilities | 54 | 7 | 8 | 11 | 15 | 13 | 12 | 61 | 50 | 46 | 32 | 61 |
| Total Liabilities | 177 | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 |
| Fixed Assets | 9 | 9 | 42 | 33 | 33 | 32 | 32 | 30 | 65 | 64 | 62 | 64 |
| CWIP | 0 | 0 | 0 | 1 | 3 | 20 | 30 | 65 | 3 | 4 | 6 | 47 |
| Investments | 138 | 72 | 49 | 53 | 56 | 53 | 52 | 60 | 71 | 62 | 72 | 72 |
| Other Assets | 30 | 46 | 25 | 26 | 35 | 38 | 30 | 47 | 71 | 90 | 100 | 129 |
| Total Assets | 177 | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 |
Below is a detailed analysis of the balance sheet data for Kilitch Drugs (India) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 16.00 Cr..
- For Reserves, as of Mar 2025, the value is 186.00 Cr.. The value appears strong and on an upward trend. It has increased from 160.00 Cr. (Mar 2024) to 186.00 Cr., marking an increase of 26.00 Cr..
- For Borrowings, as of Mar 2025, the value is 49.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 32.00 Cr. (Mar 2024) to 49.00 Cr., marking an increase of 17.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 61.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 32.00 Cr. (Mar 2024) to 61.00 Cr., marking an increase of 29.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 313.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 240.00 Cr. (Mar 2024) to 313.00 Cr., marking an increase of 73.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 64.00 Cr.. The value appears strong and on an upward trend. It has increased from 62.00 Cr. (Mar 2024) to 64.00 Cr., marking an increase of 2.00 Cr..
- For CWIP, as of Mar 2025, the value is 47.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2024) to 47.00 Cr., marking an increase of 41.00 Cr..
- For Investments, as of Mar 2025, the value is 72.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 72.00 Cr..
- For Other Assets, as of Mar 2025, the value is 129.00 Cr.. The value appears strong and on an upward trend. It has increased from 100.00 Cr. (Mar 2024) to 129.00 Cr., marking an increase of 29.00 Cr..
- For Total Assets, as of Mar 2025, the value is 313.00 Cr.. The value appears strong and on an upward trend. It has increased from 240.00 Cr. (Mar 2024) to 313.00 Cr., marking an increase of 73.00 Cr..
Notably, the Reserves (186.00 Cr.) exceed the Borrowings (49.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 4.00 | -2.00 | -4.00 | -2.00 | 5.00 | -2.00 | -13.00 | -10.00 | -10.00 | -4.00 | -8.00 | -17.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 51 | 243 | 286 | 196 | 148 | 86 | 109 | 122 | 132 | 142 | 149 | 156 |
| Inventory Days | 12 | 124 | 110 | 84 | 39 | 36 | 70 | 35 | 28 | 10 | 18 | 53 |
| Days Payable | 19 | 124 | 154 | 184 | 108 | 33 | 89 | 525 | 239 | 200 | 118 | 189 |
| Cash Conversion Cycle | 44 | 243 | 241 | 96 | 79 | 89 | 89 | -367 | -79 | -48 | 50 | 20 |
| Working Capital Days | -143 | 197 | 234 | 115 | 93 | 37 | 22 | -223 | -40 | -4 | 30 | 56 |
| ROCE % | 8% | -10% | -9% | 5% | 6% | 1% | 3% | 6% | 10% | 13% | 16% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 16.60 | 9.17 | 6.71 | 4.73 | 2.37 |
| Diluted EPS (Rs.) | 16.60 | 9.17 | 6.71 | 4.73 | 2.37 |
| Cash EPS (Rs.) | 17.44 | 10.52 | 7.59 | 5.57 | 3.71 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 125.81 | 109.62 | 96.64 | 90.03 | 83.56 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 125.81 | 109.62 | 96.64 | 90.03 | 83.56 |
| Revenue From Operations / Share (Rs.) | 123.31 | 95.99 | 89.59 | 73.31 | 44.22 |
| PBDIT / Share (Rs.) | 26.50 | 17.80 | 13.15 | 8.52 | 5.07 |
| PBIT / Share (Rs.) | 24.57 | 15.72 | 10.87 | 6.94 | 3.79 |
| PBT / Share (Rs.) | 21.44 | 12.03 | 7.71 | 6.17 | 3.30 |
| Net Profit / Share (Rs.) | 15.51 | 8.44 | 5.32 | 3.99 | 2.43 |
| NP After MI And SOA / Share (Rs.) | 16.60 | 9.08 | 6.71 | 4.73 | 2.37 |
| PBDIT Margin (%) | 21.49 | 18.54 | 14.67 | 11.62 | 11.47 |
| PBIT Margin (%) | 19.92 | 16.37 | 12.12 | 9.46 | 8.57 |
| PBT Margin (%) | 17.38 | 12.53 | 8.60 | 8.41 | 7.47 |
| Net Profit Margin (%) | 12.57 | 8.79 | 5.93 | 5.43 | 5.49 |
| NP After MI And SOA Margin (%) | 13.46 | 9.45 | 7.48 | 6.44 | 5.35 |
| Return on Networth / Equity (%) | 13.19 | 8.28 | 6.89 | 5.29 | 2.88 |
| Return on Capital Employeed (%) | 17.29 | 14.37 | 11.24 | 7.69 | 4.52 |
| Return On Assets (%) | 8.53 | 6.08 | 4.75 | 3.51 | 1.80 |
| Long Term Debt / Equity (X) | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.24 | 0.17 | 0.14 | 0.14 | 0.11 |
| Asset Turnover Ratio (%) | 0.71 | 0.67 | 0.65 | 0.48 | 0.41 |
| Current Ratio (X) | 2.06 | 2.27 | 1.84 | 1.65 | 1.10 |
| Quick Ratio (X) | 1.88 | 2.21 | 1.81 | 1.57 | 1.05 |
| Inventory Turnover Ratio (X) | 20.55 | 51.18 | 21.16 | 14.04 | 8.31 |
| Interest Coverage Ratio (X) | 8.46 | 4.83 | 4.16 | 11.08 | 10.42 |
| Interest Coverage Ratio (Post Tax) (X) | 5.95 | 3.29 | 2.68 | 6.18 | 5.99 |
| Enterprise Value (Cr.) | 619.00 | 638.35 | 218.65 | 272.89 | 130.24 |
| EV / Net Operating Revenue (X) | 3.12 | 4.14 | 1.57 | 2.39 | 1.90 |
| EV / EBITDA (X) | 14.52 | 22.29 | 10.67 | 20.55 | 16.57 |
| MarketCap / Net Operating Revenue (X) | 2.93 | 4.06 | 1.56 | 2.29 | 1.83 |
| Price / BV (X) | 2.87 | 3.56 | 1.43 | 1.88 | 0.98 |
| Price / Net Operating Revenue (X) | 2.93 | 4.06 | 1.56 | 2.29 | 1.83 |
| EarningsYield | 0.04 | 0.02 | 0.04 | 0.02 | 0.02 |
After reviewing the key financial ratios for Kilitch Drugs (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 16.60. This value is within the healthy range. It has increased from 9.17 (Mar 24) to 16.60, marking an increase of 7.43.
- For Diluted EPS (Rs.), as of Mar 25, the value is 16.60. This value is within the healthy range. It has increased from 9.17 (Mar 24) to 16.60, marking an increase of 7.43.
- For Cash EPS (Rs.), as of Mar 25, the value is 17.44. This value is within the healthy range. It has increased from 10.52 (Mar 24) to 17.44, marking an increase of 6.92.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 125.81. It has increased from 109.62 (Mar 24) to 125.81, marking an increase of 16.19.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 125.81. It has increased from 109.62 (Mar 24) to 125.81, marking an increase of 16.19.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 123.31. It has increased from 95.99 (Mar 24) to 123.31, marking an increase of 27.32.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 26.50. This value is within the healthy range. It has increased from 17.80 (Mar 24) to 26.50, marking an increase of 8.70.
- For PBIT / Share (Rs.), as of Mar 25, the value is 24.57. This value is within the healthy range. It has increased from 15.72 (Mar 24) to 24.57, marking an increase of 8.85.
- For PBT / Share (Rs.), as of Mar 25, the value is 21.44. This value is within the healthy range. It has increased from 12.03 (Mar 24) to 21.44, marking an increase of 9.41.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 15.51. This value is within the healthy range. It has increased from 8.44 (Mar 24) to 15.51, marking an increase of 7.07.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 16.60. This value is within the healthy range. It has increased from 9.08 (Mar 24) to 16.60, marking an increase of 7.52.
- For PBDIT Margin (%), as of Mar 25, the value is 21.49. This value is within the healthy range. It has increased from 18.54 (Mar 24) to 21.49, marking an increase of 2.95.
- For PBIT Margin (%), as of Mar 25, the value is 19.92. This value is within the healthy range. It has increased from 16.37 (Mar 24) to 19.92, marking an increase of 3.55.
- For PBT Margin (%), as of Mar 25, the value is 17.38. This value is within the healthy range. It has increased from 12.53 (Mar 24) to 17.38, marking an increase of 4.85.
- For Net Profit Margin (%), as of Mar 25, the value is 12.57. This value exceeds the healthy maximum of 10. It has increased from 8.79 (Mar 24) to 12.57, marking an increase of 3.78.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.46. This value is within the healthy range. It has increased from 9.45 (Mar 24) to 13.46, marking an increase of 4.01.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.19. This value is below the healthy minimum of 15. It has increased from 8.28 (Mar 24) to 13.19, marking an increase of 4.91.
- For Return on Capital Employeed (%), as of Mar 25, the value is 17.29. This value is within the healthy range. It has increased from 14.37 (Mar 24) to 17.29, marking an increase of 2.92.
- For Return On Assets (%), as of Mar 25, the value is 8.53. This value is within the healthy range. It has increased from 6.08 (Mar 24) to 8.53, marking an increase of 2.45.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.13, marking an increase of 0.13.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.17 (Mar 24) to 0.24, marking an increase of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.71. It has increased from 0.67 (Mar 24) to 0.71, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has decreased from 2.27 (Mar 24) to 2.06, marking a decrease of 0.21.
- For Quick Ratio (X), as of Mar 25, the value is 1.88. This value is within the healthy range. It has decreased from 2.21 (Mar 24) to 1.88, marking a decrease of 0.33.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 20.55. This value exceeds the healthy maximum of 8. It has decreased from 51.18 (Mar 24) to 20.55, marking a decrease of 30.63.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.46. This value is within the healthy range. It has increased from 4.83 (Mar 24) to 8.46, marking an increase of 3.63.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.95. This value is within the healthy range. It has increased from 3.29 (Mar 24) to 5.95, marking an increase of 2.66.
- For Enterprise Value (Cr.), as of Mar 25, the value is 619.00. It has decreased from 638.35 (Mar 24) to 619.00, marking a decrease of 19.35.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.12. This value exceeds the healthy maximum of 3. It has decreased from 4.14 (Mar 24) to 3.12, marking a decrease of 1.02.
- For EV / EBITDA (X), as of Mar 25, the value is 14.52. This value is within the healthy range. It has decreased from 22.29 (Mar 24) to 14.52, marking a decrease of 7.77.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.93. This value is within the healthy range. It has decreased from 4.06 (Mar 24) to 2.93, marking a decrease of 1.13.
- For Price / BV (X), as of Mar 25, the value is 2.87. This value is within the healthy range. It has decreased from 3.56 (Mar 24) to 2.87, marking a decrease of 0.69.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.93. This value is within the healthy range. It has decreased from 4.06 (Mar 24) to 2.93, marking a decrease of 1.13.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.04, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Kilitch Drugs (India) Ltd:
- Net Profit Margin: 12.57%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.29% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.19% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.95
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.88
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 22.5 (Industry average Stock P/E: 52.22)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.24
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.57%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | C-301/2, M.I.D.C., New Mumbai Maharashtra 400705 | info@kilitch.com http://www.kilitch.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mukund P Mehta | Managing Director |
| Mr. Bhavin Mukund Mehta | Whole Time Director |
| Mrs. Mira B Mehta | Whole Time Director |
| Mr. Hemang J Engineer | Independent Director |
| Mr. Venkita Subramanian Rajan | Independent Director |
| Prof. Vasudev Krishna Murti | Independent Director |
| Mr. Dipen J Jain | Independent Director |
FAQ
What is the intrinsic value of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd's intrinsic value (as of 02 December 2025) is 351.63 which is 0.95% lower the current market price of 355.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 621 Cr. market cap, FY2025-2026 high/low of 500/265, reserves of ₹186 Cr, and liabilities of 313 Cr.
What is the Market Cap of Kilitch Drugs (India) Ltd?
The Market Cap of Kilitch Drugs (India) Ltd is 621 Cr..
What is the current Stock Price of Kilitch Drugs (India) Ltd as on 02 December 2025?
The current stock price of Kilitch Drugs (India) Ltd as on 02 December 2025 is 355.
What is the High / Low of Kilitch Drugs (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Kilitch Drugs (India) Ltd stocks is 500/265.
What is the Stock P/E of Kilitch Drugs (India) Ltd?
The Stock P/E of Kilitch Drugs (India) Ltd is 22.5.
What is the Book Value of Kilitch Drugs (India) Ltd?
The Book Value of Kilitch Drugs (India) Ltd is 152.
What is the Dividend Yield of Kilitch Drugs (India) Ltd?
The Dividend Yield of Kilitch Drugs (India) Ltd is 0.00 %.
What is the ROCE of Kilitch Drugs (India) Ltd?
The ROCE of Kilitch Drugs (India) Ltd is 15.7 %.
What is the ROE of Kilitch Drugs (India) Ltd?
The ROE of Kilitch Drugs (India) Ltd is 12.6 %.
What is the Face Value of Kilitch Drugs (India) Ltd?
The Face Value of Kilitch Drugs (India) Ltd is 10.0.